flunarizine and Disorders-of-Excessive-Somnolence

flunarizine has been researched along with Disorders-of-Excessive-Somnolence* in 1 studies

Trials

1 trial(s) available for flunarizine and Disorders-of-Excessive-Somnolence

ArticleYear
Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2014, Volume: 271, Issue:11

    Migrainous vertigo is a common cause of dizziness presenting to an otorhinolaryngology/otoneurology clinic. Although it causes a substantial burden to the individual and society there are no randomized controlled trails on prophylactic medication for this condition. Flunarizine, a calcium channel blocker has been used effectively in both migraine and vestibular conditions. This randomized control trial was undertaken in a tertiary academic referral center to evaluate the efficacy of flunarizine in patients with migrainous vertigo when compared to non-specific vestibular treatment of betahistine and vestibular exercises. The effect of flunarizine on two particularly disabling symptoms of vertigo and headache was studied. A total of 48 patients who were diagnosed with definitive migrainous vertigo completed the study of 12 weeks duration. Patients in arm A received 10-mg flunarizine daily along with betahistine 16 mg and paracetamol 1 gm during episodes, and arm B received only betahistine and paracetamol during episodes. Symptom scores were noted at the start of the study and at the end of 12 weeks. Analysis of the frequency of vertiginous episodes showed a significant difference between arm A and arm B (p = 0.010) and improvement in severity of vertigo between the two groups (p = 0.046). Headache frequency and severity did not improve to a significant degree in arm A as compared to arm B. The main side effects were weight gain and somnolence and this was not significantly different between the two groups. Flunarizine (10 mg) is effective in patients with migrainous vertigo who suffer from considerable vestibular symptoms.

    Topics: Acetaminophen; Adolescent; Adult; Aged; Betahistine; Calcium Channel Blockers; Disorders of Excessive Somnolence; Drug Therapy, Combination; Female; Flunarizine; Histamine Agonists; Histamine Antagonists; Humans; Male; Middle Aged; Migraine Disorders; Vertigo; Weight Gain; Young Adult

2014